Working… Menu
Trial record 71 of 143 for:    NIFEDIPINE

Amlodipine Prevents Morning Blood Pressure Surge Study (ARMORS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01030081
Recruitment Status : Completed
First Posted : December 11, 2009
Last Update Posted : May 22, 2014
Information provided by (Responsible Party):
Ji-Guang Wang, Shanghai Jiao Tong University School of Medicine

Brief Summary:
  1. Study name:Amlodipine Prevents Morning Blood Pressure Surge Study
  2. Study drugs:amlodipine (Norvasc®) and nifedipine GITS (Adalat®)
  3. Rationale: Several recent studies compared 24-h blood pressure lowering effect of these 2 dihydropyridine drugs, amlodipine and nifedipine GITS, but produced inconsistent results. Therefore, a randomized controlled trial with a larger sample size is required to compare these 2 dihydropyridines in the blood pressure control over 24 hours in general and during early morning hours and at night in particular.
  4. Objective: The primary objective of this study is to test the hypothesis that amlodipine compared with nifedipine GITS has a stronger effect in preventing morning blood pressure surge (4 am to 8 am) in mild to moderate hypertensive patients.The secondary objective of the study is to compare the effects of amlodipine and nifedipine GITS in reducing nighttime blood pressure (10 pm to 4 am) in patients with a decreased nocturnal blood pressure fall.
  5. Study design: The present study is designed as a randomized, actively controlled, multi-centre parallel group trial (phase Ⅳ) with two equally sized treatment groups: amlodipine and nifedipine GITS.
  6. Study population: 500 hypertensive patients meet the inclusion/exclusion criteria.
  7. Randomization and treatment: After stratification for centre, 500 eligible patients will be randomized into 2 groups. 250 will receive amlodipine 5 mg per day, and 250 will receive nifedipine GITS 30 mg per day. At 4 weeks of follow-up, the drug dosage per day may increase to 10 mg of amlodipine and 60 mg of nifedipine GITS, if blood pressure measured in doctor's office cannot be controlled to a level below 140/90 mm Hg. If there were no compelling indication, no other antihypertensive drug is allowed during the 2-month trial.
  8. Follow up: All patients should give written informed consent at entry into the present study. In addition to 24-h ambulatory blood pressure monitoring, patients should also undergo a questionnaire survey and clinical measurements including clinic blood pressure. Patients will be followed up at the end of 4 weeks and 8 weeks after randomization.
  9. Sample size estimation: The number of required subject for the whole trial is 500.
  10. Timeline: October 2009 to July 2013.
  11. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Amlodipine (Norvasc®) Drug: Nifedipine GITS (Adalat® XL 30 Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 510 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Randomized Controlled Phase Ⅳ Trial With Two Equally Sized Treatment Groups: Amlodipine And Nifedipine GITS
Study Start Date : October 2009
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Amlodipine (Norvasc®) Drug: Amlodipine (Norvasc®)
Amlodipine (Norvasc®), tablet, 5 mg

Active Comparator: Nifedipine GITS (Adalat® XL 30) Drug: Nifedipine GITS (Adalat® XL 30
Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg

Primary Outcome Measures :
  1. the change from baseline in the mean systolic blood pressure during the morning hours (4 am to 8 am) of the first 24-hour ambulatory blood pressure monitoring at week 8 after randomization [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. the change from baseline in mean systolic blood pressure during the morning, mean systolic blood pressure at night, mean systolic blood pressure during the morning after missed dose, mean 24 h systolic blood pressure and mean daytime blood pressure [ Time Frame: 4, 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 40 to 70 years old.
  • Untreated patients or those on monotherapy of antihypertensive drugs but with uncontrolled blood pressure in the ranges of 140-160/90-100 mmHg.
  • Patients on antihypertensive medication should discontinue their antihypertensive treatment for at least 4 weeks. During the 4 weeks run-in period, all patients should have 2 clinic visits. At each visit, blood pressure will be measured 3 times consecutively. The average of these 6 readings from 2 clinic visits should be in the range of 140-180 systolic or 90-110 diastolic mm Hg. 24-h mean blood pressure should be equal to or higher than 130 mm Hg systolic and 80 mm Hg diastolic.
  • The patients should sign the consent form prior to the participation in the trial, adhere to the study design, and can visit the outpatient clinic on his/her own.

Exclusion Criteria:

  • With life-threatening disease.
  • With myocardial infarction or stroke in the last 2 years.
  • With contraindications to a dihydropyridine calcium channel blocker.
  • Current participation in another trial or trials.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01030081

Layout table for location information
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China, 200025
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Layout table for investigator information
Principal Investigator: Jiguang Wang, MD, PhD Shanghai Jiao Tong University School of Medicine

Layout table for additonal information
Responsible Party: Ji-Guang Wang, Director, Shanghai Jiao Tong University School of Medicine Identifier: NCT01030081     History of Changes
Other Study ID Numbers: ARMORS
First Posted: December 11, 2009    Key Record Dates
Last Update Posted: May 22, 2014
Last Verified: May 2014
Keywords provided by Ji-Guang Wang, Shanghai Jiao Tong University School of Medicine:
24 hour blood pressure
morning blood pressure surge
nifedipine GITS
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents